Skip to content

Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin

Split-Face Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01046565
Enrollment
75
Registered
2010-01-12
Start date
2010-01-31
Completion date
2010-02-28
Last updated
2022-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Manifestations

Brief summary

The purpose of this study is to compare the tolerability of Differin® (adapalene) Cream, 0.1% to Differin® Lotion, 0.1% in subjects with healthy skin treated once a day for three (3) weeks.

Interventions

adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks

adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks

Sponsors

Galderma R&D
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Males or females aged 18 years and older * Subjects with healthy skin as determined by the clinical grader.

Exclusion criteria

* Subjects with a degree of skin pigmentation that interferes with the reading of skin reactions. * Subjects with a condition or who are in a situation, which in the investigator's opinion may put the subject at risk, may confound study results, or may interfere with the subject's participation in the study * Subjects with known allergy to one of the components of the study drugs (refer to the package insert for Differin® Cream 0.1% and the investigator's brochure for Differin® Lotion 0.1%) * Subjects who have participated in another investigational drug or device research study within 30 days of enrollment. * Subjects with a washout period for topical treatment on the treated area less than 1 week for corticosteroids and/or 4 weeks for retinoids. * Subjects with a washout period for systemic treatment less than 1 week for medications that may increase photosensitivity and/or 4 weeks for corticosteroids and/or 6 months for retinoids. * Subjects with current sunburn, eczema, atopic dermatitis, perioral dermatitis or rosacea on the area to be treated. * Subjects who foresee unprotected and intense UV exposure during the study (mountain sports, UV radiation, sunbathing, etc.).

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Category of the Tolerability Assessments (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3.baseline to week 3Number of participants who were a success with regard to worst post-baseline tolerability assessment scores in each category of the tolerability assessments from baseline to week 3. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success for each category was defined as a tolerability score of 0.

Secondary

MeasureTime frameDescription
6 Question Subject Cosmetic Acceptability Questionnaireweek 3Number of participants in each category (Differin® Lotion, Differin® Cream or No Preference) for each question of the Subject Cosmetic Acceptability Questionnaire at week 3.

Countries

United States

Participant flow

Recruitment details

Dates of recruitment period: First subject was enrolled on January 11, 2010 and the last subject was enrolled on January 11, 2010. Types of location: Investigative site was located at a research center.

Pre-assignment details

Wash-out period up to baseline for topical treatment on the treated area was less than 1 week for corticosteroids and/or 4 weeks for retinoids; for systemic treatment, it was less than 1 week for medications that may have increased photosensitivity and/or 4 weeks for corticosteroids and/or 6 months for retinoids.

Participants by arm

ArmCount
Differin® Lotion 0.1% and Differin Cream 0.1%
Adapalene Lotion 0.1% - apply topically to one side of the face once daily for 3 weeks. Adapalene Cream 0.1% - apply topically to the opposite side of the face once daily for 3 weeks. Subjects were randomized to receive Adapalene Cream 0.1% on one side of the face and Adapalene Lotion 0.1% on the other side of the face.
75
Total75

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyAdverse Event2
Overall StudyWithdrawal by Subject7

Baseline characteristics

CharacteristicDifferin® Lotion 0.1% and Differin Cream 0.1%
Age, Continuous44.75 years
STANDARD_DEVIATION 13.39
Sex: Female, Male
Female
59 Participants
Sex: Female, Male
Male
16 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 750 / 75
serious
Total, serious adverse events
0 / 750 / 75

Outcome results

Primary

Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Category of the Tolerability Assessments (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3.

Number of participants who were a success with regard to worst post-baseline tolerability assessment scores in each category of the tolerability assessments from baseline to week 3. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success for each category was defined as a tolerability score of 0.

Time frame: baseline to week 3

Population: Per protocol

ArmMeasureGroupValue (NUMBER)
Differin® Lotion 0.1%Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Category of the Tolerability Assessments (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3.Erythema35 participants
Differin® Lotion 0.1%Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Category of the Tolerability Assessments (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3.Scaling58 participants
Differin® Lotion 0.1%Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Category of the Tolerability Assessments (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3.Dryness46 participants
Differin® Lotion 0.1%Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Category of the Tolerability Assessments (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3.Stinging/Burning57 participants
Differin Cream 0.1%Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Category of the Tolerability Assessments (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3.Stinging/Burning60 participants
Differin Cream 0.1%Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Category of the Tolerability Assessments (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3.Erythema33 participants
Differin Cream 0.1%Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Category of the Tolerability Assessments (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3.Dryness44 participants
Differin Cream 0.1%Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Category of the Tolerability Assessments (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3.Scaling61 participants
Secondary

6 Question Subject Cosmetic Acceptability Questionnaire

Number of participants in each category (Differin® Lotion, Differin® Cream or No Preference) for each question of the Subject Cosmetic Acceptability Questionnaire at week 3.

Time frame: week 3

Population: ITT (Intent to Treat)

ArmMeasureGroupValue (NUMBER)
Differin® Lotion 0.1%6 Question Subject Cosmetic Acceptability QuestionnaireWhich side was easier to apply?17 participants
Differin® Lotion 0.1%6 Question Subject Cosmetic Acceptability QuestionnaireWhich side absorbed into your skin more quickly?25 participants
Differin® Lotion 0.1%6 Question Subject Cosmetic Acceptability QuestionnaireWhich side had less odor?7 participants
Differin® Lotion 0.1%6 Question Subject Cosmetic Acceptability QuestionnaireWhich side felt better on your skin?27 participants
Differin® Lotion 0.1%6 Question Subject Cosmetic Acceptability QuestionnaireWhich side left less residue on your skin?15 participants
Differin® Lotion 0.1%6 Question Subject Cosmetic Acceptability QuestionnaireGenerally, which side did you prefer?26 participants
Differin Cream 0.1%6 Question Subject Cosmetic Acceptability QuestionnaireGenerally, which side did you prefer?23 participants
Differin Cream 0.1%6 Question Subject Cosmetic Acceptability QuestionnaireWhich side was easier to apply?14 participants
Differin Cream 0.1%6 Question Subject Cosmetic Acceptability QuestionnaireWhich side felt better on your skin?22 participants
Differin Cream 0.1%6 Question Subject Cosmetic Acceptability QuestionnaireWhich side left less residue on your skin?22 participants
Differin Cream 0.1%6 Question Subject Cosmetic Acceptability QuestionnaireWhich side absorbed into your skin more quickly?23 participants
Differin Cream 0.1%6 Question Subject Cosmetic Acceptability QuestionnaireWhich side had less odor?4 participants
No Preference6 Question Subject Cosmetic Acceptability QuestionnaireWhich side absorbed into your skin more quickly?27 participants
No Preference6 Question Subject Cosmetic Acceptability QuestionnaireWhich side had less odor?64 participants
No Preference6 Question Subject Cosmetic Acceptability QuestionnaireGenerally, which side did you prefer?26 participants
No Preference6 Question Subject Cosmetic Acceptability QuestionnaireWhich side felt better on your skin?26 participants
No Preference6 Question Subject Cosmetic Acceptability QuestionnaireWhich side was easier to apply?44 participants
No Preference6 Question Subject Cosmetic Acceptability QuestionnaireWhich side left less residue on your skin?38 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026